Elagolix Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis
Status:
Completed
Trial end date:
2008-11-24
Target enrollment:
Participant gender:
Summary
This study is designed to assess the effects of elagolix versus subcutaneous depot
medroxyprogesterone acetate (DMPA-SC; also known as depo-provera) on bone mineral density
(BMD) during treatment for 24 weeks with a subsequent 24-week post-treatment period.